Paris Cedex 15

• Stroke in childhood due to inflammatory narrowing of blood vessels: Treatment with steroids Pending
  2022-500631-36-00 5 Focal cerebral arteriopathy and childhood stroke Focal cerebral arteri
• Clinical study to check the Efficacy and Safety of Mitapivat in Patients with Sickle Cell Disease Pending
  2024-515202-84-00 10 Anemia in subjects with sickle cell disease (SCD)
• Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or … Pending
  2024-516052-17-01 10 Patients with a diagnosis of IgAV according to Chapel Hill Consensus C
• Evaluation of the safety and efficacy of Bevacizumab in patients with persistent respiratory disorders after COVID-19 infection Pending
  2024-520308-24-00 4 Adult patients with persistent dyspnea more than 3 months after acute
• A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treat … Pending
  2025-523735-19-00 5 Metastatic Microsatellite Stable Colorectal Cancer
• A clinical study to evaluate the effects of RO7795068 in participants with obesity or overweight and type 2 diabetes Recruiting
  2025-523106-32-00 5 2026-05-25 Obesity or Overweight and Type 2 Diabetes
• Postoperative anti-infective strategy following pancreaticoduodenectomy in patients with preoperative biliary stent FRENCH24 ANIS Recruiting
  2024-515181-14-00 5 2026-05-20 Patients with preoperative biliary stent treated by pancreaticoduodene
• Rituximab in patients with ST-elevation myocardial infarction. A phase 2 placebo-controlled randomized clinical trial. Recruiting
  2022-501893-21-00 4 2022-05-03 Acute myocardial infarction
• Avacopan added to standard-of-care therapy in ANCA-associated vasculitis with severe kidney involvement Recruiting
  2024-519620-24-01 5 2026-06-01 ANCA-associated vasculitis
• Pharmacokinetics, Efficacy and Safety of Twice Daily Dosing Regimen of Hydroxycarbamide Dispersible Tablets in Children with Sickle Cell Dis … Recruiting
  2024-513750-30-00 4 2026-03-25 Sickle Cell Disease
• A Study of Evorpacept (ALX148) in Patients with Metastatic HER2-Positive Breast Cancer Recruiting
  2025-522012-16-00 4 2026-03-13 Breast Cancer
• A study of sepiapterin in participants with phenylketonuria (PKU) (EPIPHENY) Recruiting
  2024-514435-20-00 5 2025-12-23 Phenylketonuria
• PHASE 2B TRIAL OF AEF0217 IN PARTICIPANTS WITH DOWN SYNDROME Recruiting
  2025-521013-10-00 4 2025-12-11 Treatment of behavioural and cognitive impairments in Down syndrome.
• A study to evaluate the safety and efficacy of two dose levels of ONO-4578 with Opdivo®, in combination with mFOLFOX6 and bevacizumab versus … Recruiting
  2024-519590-19-00 4 2025-11-25 PD-L1 positive advanced colorectal cancer
• A Phase 3 study of NBTXR3 with or without cetuximab in LA-HNSCC Recruiting
  2024-520386-31-00 5 2025-09-22 Locally Advanced Head & Neck Squamous Cell Carcinoma
• A trial to learn how safe baxdrostat is and how well it works in adults with primary aldosteronism Recruiting
  2025-520740-16-00 5 2025-09-19 Primary Aldosteronism defined by excess aldosterone secretion
• A Phase 2 Study of MZE829 in Adults with APOL1 Kidney Disease Recruiting
  2024-517525-10-00 4 2025-09-15 APOL1 Kidney Disease (AKD)
• Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer … Recruiting
  2024-516982-35-00 5 2025-09-11 Ovarian Cancer
• Prevention of secondary infections by interferon gamma in ICU-acquired sustained immune-suppression: a randomized trial Recruiting
  2024-516780-93-00 5 2025-07-09 Sustained immunosuppression
• Randomized controlled multicenter study comparing steroid therapy plus anticoagulants to steroid therapy alone in deep venous thrombosis of … Recruiting
  2023-510262-27-00 4 2025-06-24 newly diagnosed or relapsing deep venous thrombosis related to Behçet’
• ATLANTIS Protamine - Antagonization of heparin with protamine sulfate to reduce all neurologic ischemic and hemorrhagic events after transca … Recruiting
  2023-504511-32-00 5 2025-05-24 Any patients ≥18 years old, eligible for transfemoral TAVI with covera
• EvER-ILD 3 : Evaluation of Efficacy and safety of Rituximab and mycophenolate mofetil combination in patients with Interstitial Lung Disease … Recruiting
  2023-510507-21-00 10 2025-01-08 Intersitial lung disease related to systemic sclerosis
• Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting
  2023-509811-98-00 4 2025-01-07 Patients with HER2-positive locally advanced inoperable or metastatic
• Short versus long antiplatelet therapy after TAVI Recruiting
  2023-508208-40-00 10 2024-11-21 All adult patients with successful transfemoral trans-aortic valve imp

Showing 1–24 of 63 trials